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Background. In 2010, mass vaccination with a then-new meningococcal A polysaccharide–tetanus toxoid pro-
tein conjugate vaccine (PsA-TT, or MenAfriVac) was undertaken in 1- to 29-year-olds in Bamako, Mali. Whether
vaccination with PsA-TT effectively boosts tetanus immunity in a population with heterogeneous baseline tetanus
immunity is not known. We assessed the impact of PsA-TT on tetanus toxoid (TT) immunity by quantifying age-
and sex-speciﬁc immunity prior to and 2 years after introduction.
Methods. Using a household-based, age-stratiﬁed design, we randomly selected participants for a prevaccination
serological survey in 2010 and a postvaccination survey in 2012. TT immunoglobulin G (IgG) antibodies were quan-
tiﬁed and geometric mean concentrations (GMCs) pre- and postvaccination among all age groups targeted for vac-
cination were compared. The probability of TT IgG levels ≥0.1 IU/mL (indicating short-term protection) and ≥1.0
IU/mL (indicating long-term protection) by age and sex was determined using logistic regression models.
Results. Analysis of 793 prevaccination and 800 postvaccination sera indicated that while GMCs were low pre–
PsA-TT, signiﬁcantly higher GMCs in all age–sex strata were observed 2 years after PsA-TT introduction. The per-
centage with short-term immunity increased from 57.1% to 88.4% (31.3-point increase; 95% conﬁdence interval
[CI], 26.6–36.0;, P < .0001) and with long-term immunity increased from 20.0% to 58.5% (38.5-point increase;
95% CI, 33.7–43.3; P < .0001) pre- and postvaccination.
Conclusions. Signiﬁcantly higher TT immunity was observed among vaccine-targeted age groups up to 2 years
after Mali’s PsA-TT mass vaccination campaign. Our results, combined with evidence from clinical trials, strongly
suggest that conjugate vaccines containing TT such as PsA-TT should be considered bivalent vaccines because of
their ability to boost tetanus immunity.
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In recent years, conjugate vaccines that link the polysac-
charides on the outer surface of bacterial pathogens to
protein carriers such as tetanus toxoid (TT) have been
developed to protect against Neisseria meningitidis,
Haemophilus inﬂuenzae type b (Hib), Streptococcus pneu-
moniae, and other pathogens [1]. Conjugate bacterial
vaccines have markedly improved prevention and control
efforts beyond results obtained with polysaccharide vac-
cines alone [2]. Conjugate vaccines have had signiﬁcantly
greater impact than polysaccharide vaccines because the
presence of a carrier protein transforms the T-cell–ind-
ependent immune response into a T-cell–dependent re-
sponse, inducing immunologic memory and a strong
immune response even among infants [3]. In addition,
meningococcal, pneumococcal, and Hib conjugate vac-
cines have been shown to effectively prevent the acquisi-
tion of nasopharyngeal carriage of vaccine strains [2].
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The 2010 introduction of an affordable group A meningococcal
polysaccharide–TT protein conjugate vaccine, PsA-TT, or
MenAfriVac, through mass vaccination campaigns targeting in-
dividuals aged 1–29 years in the African meningitis belt, has led
to a dramatic decrease in group A meningococcal disease [4]. In
addition to 10 µg of group A polysaccharide, PsA-TT contains
10–33 µg of TT [5], a level similar to other TT-containing vac-
cines. As a result, PsA-TT may boost immunity to tetanus in
populations, adding beneﬁt beyond prevention of meningococ-
cal disease. Boosting tetanus immunity would be especially ben-
eﬁcial in resource-limited settings where tetanus incidence is
highest and in areas where not all individuals have had prior
exposure to sufﬁcient doses of TT-containing vaccines to main-
tain immunity.
Currently, the World Health Organization (WHO) recom-
mends that 3 doses of a TT-containing vaccine be administered
in the ﬁrst year of life as part of routine immunization programs
with 2 booster doses of TT-containing vaccines given during
childhood followed by vaccination of pregnant women to pre-
vent neonatal tetanus [6]. Meeting the Global Vaccine Action
Plan’s (GVAP) target of 90% coverage nationally and >80% cov-
erage with at least 3 doses of diphtheria-tetanus-pertussis
vaccine in every district by 2015 remains a challenge for
many low- and middle-income countries. By 2013, an estimated
66% of countries achieved the former target [7], and by 2012,
30% achieved the latter target worldwide [8]. Evidence suggests
that 3 doses of TT-containing vaccine in the ﬁrst year of life pro-
vides 3–5 years of protection, a booster dose between 4 and 7
years of age protects through adolescence, and another booster
in adolescence protects through adulthood for 20–30 years [9].
However, vaccination schedules and vaccination coverage vary
by country. In Mali, national immunization includes adminis-
tration of pentavalent diphtheria, TT, pertussis, H. inﬂuenzae,
and hepatitis B vaccine at 6, 10, and 14 weeks, with additional
TT vaccination during pregnancy [10]. Mali does not adminis-
ter adolescent TT boosters as part of its routine immunization
program [10]. WHO-UNICEF estimates that in 2010, 82% of
12- to 23-month-olds in Mali received at least 1 dose of TT-con-
taining vaccine, and 76% received all 3 recommended Expanded
Programme on Immunization (EPI) doses [11].
Tetanus remains an ongoing challenge in some low- and
middle-income countries [12], and an estimated 58 000 neona-
tal deaths due to tetanus occurred worldwide in 2010 [13]. Sev-
eral countries located in the African meningitis belt, including
Mali, Niger, Nigeria, and Chad had not eliminated maternal
and neonatal tetanus as of mid-2014 [14]; only 11% of countries
in the African region achieved both of the GVAP coverage goals
by 2012 [15]. Enhanced protection against tetanus might be
achieved as a result of vaccination with PsA-TT. To determine
whether PsA-TT boosts tetanus immunity, we assessed the im-
pact of the PsA-TT in Mali on population-level TT immunity
by quantifying TT-speciﬁc IgG levels before and 2 years after
the December 2010 PsA-TT mass vaccination campaign.
METHODS
We conducted 2 cross-sectional serologic surveys in Mali’s
capital, Bamako, and villages nearby immediately prior to and
2 years after a PsA-TT mass vaccination campaign. The PsA-TT
campaign was launched in December 2010 and targeted all in-
dividuals 1–29 years of age during a 4-week period in the south
of the country, including the areas we surveyed. In January
2011, an evaluation of the PsA-TT campaign vaccination cover-
age level was undertaken in several districts of Bamako. Overall,
93% (95% conﬁdence interval [CI], 92.6%–93.5%) of eligible
participants were vaccinated with PsA-TT, with somewhat
higher coverage both among children aged 1–4 years (97% of
both males and females) and adolescents aged 5–14 years
(98% of males and 96% of females) compared with adults
aged 15–29 years (88% of males and 86% of females) [16].
Prevaccination Serologic Survey
The prevaccination seroprevalence survey was conducted as
part of the African Meningococcal Carriage Consortium
(MenAfriCar) research program, which aimed to assess the im-
pact of the 2010 introduction of PsA-TT on meningococcal car-
riage in Africa. MenAfriCar’s methodologies have been detailed
previously [17]. In brief, participants were selected randomly
from the Djicoroni para district of Bamako and from Narena
and Siby, neighboring villages to the southwest of Bamako,
using ahousehold-based, age-stratiﬁed samplingdesign, drawing
from the approximately 78 000 residents in Djicoroni para
identiﬁed through the Center for Vaccine Development
(CVD)–Mali’s demographic surveillance system and from the
approximately 2000 residents identiﬁed through a census con-
ducted in Narena and Siby for the purposes of this survey.
Participants were eligible if they were aged ≥6 months, had
no acute or chronic illness, and if they or their parent or guard-
ian provided consent. Participants responded to a questionnaire
and provided up to 5 mL of blood.
Postvaccination Serological Survey
The postvaccination seroprevalence survey was conducted as
part of the US National Institutes of Health–funded PsA-TT
(MenAfriVac) Antibody Persistence (MAP) study, which was
designed to assess the impact of the 2010 introduction of
PsA-TT on population-level immunity and the duration of pro-
tection against meningococcal disease provided by the vaccine
[18]. Participants were randomly selected from the Banconi
district of Bamako using a household-based, age-stratiﬁed
sampling design drawing from the >130 000 residents identiﬁed
through the CVD-Mali’s demographic surveillance system.
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Participants were eligible if they were 1–29 years old during the
2010 PsA-TT campaign, were living in Banconi at the time of
the campaign and at the time of the survey, had not previously
been vaccinated with PsA-TT as a participant in a clinical trial,
had no acute or chronic illness, and if they or their parent or
guardian provided consent. Participants responded to a ques-
tionnaire and provided up to 8.5 mL of blood.
Laboratory Methods
In both surveys, blood samples were collected and allowed to
clot before being stored in a cool box (2°C–8°C). Samples
were transported to the laboratory at CVD-Mali in Bamako
within 4–6 hours where the serum was extracted, aliquoted,
and stored at−20°C for the ﬁrst survey and−80°C for the second
survey prior to shipment on dry ice to the Vaccine Evaluation
Unit, Public Health England (Manchester, United Kingdom)
for TT IgG antibody level assessment.
Tetanus toxoid (National Institute for Biological Standards
and Control [NIBSC], Hertfordshire, UK) was coupled to car-
boxylated microspheres (12.5 × 106 microspheres/mL; Lumi-
nex, Texas) using a 2-step carbodiimide reaction [19, 20].
Carboxylated microspheres were activated in phosphate-
buffered saline (PBS; pH 7.3) containing 5 mg/mL 1-ethyl-3
(3-dimethylamino-propyl) carbodiimide-HCl and 5 mg/mL
N-hydroxysulfosuccinimide (Sulpho-NHS; both Thermo Scien-
tiﬁc, Cambridge, UK). Activated microspheres were then cou-
pled to TT (1 mg/mL; NIBSC) and brieﬂy vortex-mixed for
10 seconds, prior to incubation with shaking at 50 rpm at
room temperature for 1.5 hours in the dark. Following this,
the microspheres were washed 3 times with PBS (pH 7.3) by
centrifugation (13 000 rpm for 2 minutes). On the ﬁnal wash,
microspheres were resuspended in 1 mL PBS and transferred
to protein LoBind Eppendorf tubes (Eppendorf, Stevenage,
UK) for storage in the dark at 4°C–8°C.
Tetanus toxoid–coupled beads were then used for the quan-
tiﬁcation of TT IgG antibodies using a ﬂuorescent bead–based
assay. A 10-point standard curve of 4-fold dilutions of human
TE-3 standard reference serum (NIBSC; starting dilution 1/20)
was prepared in serum diluent (1 × PBS containing 0.05%
Tween 20 [Sigma-Aldrich, Dorset, UK] and 2% newborn bovine
serum [Labtech International Ltd, East Sussex, UK]). Each dilu-
tion of standard, serum samples and quality control serum (25
µL of each) were diluted 1:100 in serum diluent and run in du-
plicate on the plate. A concentration of 5000 microspheres/re-
gion/well (25 µL) and test and control sera were incubated in
a 96-well MV Multiscreen ﬁlter plate (Merck, Millipore, Massa-
chusetts) for 20 minutes at RT with shaking at 500 rpm in the
dark. Plates were washed twice by vacuum ﬁltration and then
100 µL of a 1:200 dilution of R-phycoerythrin conjugated anti-
human IgG (Stratech Scientiﬁc Ltd, Suffolk, UK) in PBS was
added to each well and plates were incubated for 20 minutes
with shaking (as previously, in the dark). Following another
wash, the beads were resuspended in a ﬁnal volume of 125 µL
PBS-T and shaken for 5 minutes prior to reading on a Bio-
Plex system (Bio-Rad, Hertfordshire, UK). Data were acquired
using Bio-Plex Manager version 4 (Bio-Rad). Data for unknown
test sera were generated from a 5-parameter logistic standard
curve for the relevant reference serum and converted to inter-
national units (IU/mL).
Statistical Analysis
In the prevaccination survey, ﬁeld and laboratory data were re-
corded on specially designed paper forms and converted to an
electronic format automatically using the TeleForm system (Tele-
form software version 10.4.1, HPAutonomy). In the postvaccina-
tion survey, ﬁeld and laboratory data were entered directly into
specially designed Microsoft Access (Microsoft Ofﬁce) databases
on small laptops. TT IgG data were reported in Microsoft Excel
(Microsoft Ofﬁce). All data were merged, managed, and analyzed
using Stata SE 13.1 (StataCorp LP, College Station, Texas).
Age was deﬁned as age at enrollment, which occurred be-
tween September and December 2010 for the prevaccination
survey and age on 1 December 2010 for the postvaccination sur-
vey to assess cohort effects because we are interested in whether
age-speciﬁc immunity, which would be expected to wane over
time, was boosted by PsA-TT in cohorts of individuals targeted
for PsA-TT vaccination. Age- and sex-speciﬁc pre- and postvac-
cination geometric mean concentrations (GMCs) and 95% CIs
for TT IgG were calculated. To correct for the skewness of the
distribution of TT IgG concentrations, the variable was log
(base 10) transformed and differences were assessed using t
tests on the log-transformed variable. Point estimates and CIs
were back-transformed for presentation.
Data were analyzed to determine the proportion of partici-
pants before and after PsA-TT introduction with TT IgG re-
sponse of ≥0.1 IU/mL and ≥1.0 IU/mL. The former is a
marker of short-term immunity [9, 21], and individuals with
concentrations above this threshold have evidence of protection
against tetanus that is likely to wane within a year. However,
cases have occurred in individuals with higher concentrations
of antibody [21]. Therefore, TT IgG concentrations of ≥1.0
IU/mL are putative markers of long-term protection against tet-
anus that is likely to persist, and individuals with IgG levels in
this range have evidence of recent boosting of tetanus immunity
[21]. The 2-sample test of proportions was used to assess differ-
ences in the proportion protected within age–sex strata before
and after vaccination. Multivariate logistic regression models
were developed to investigate the association between age and
sex with IgG levels at or above 0.1 IU/mL and 1.0 IU/mL, ac-
counting for the clustered sampling design. The probability of
short-term and long-term immunity by age and sex was pre-
dicted postestimation based on these models.
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Ethics Approval
The prevaccination study was approved by the ethics commit-
tees of the University of Bamako and the London School of Hy-
giene and Tropical Medicine. The postvaccination study was
approved by the ethics committee of the University of Bamako
and the institutional review boards at Princeton University and
the University of Minnesota.
RESULTS
In the prevaccination survey, 800 participants were enrolled
between September and December 2010 prior to the mid-
December 2010 PsA-TT mass vaccination campaign, which
lasted approximately 4 weeks; sera from 793 of these partici-
pants was available for analysis. In the postvaccination survey,
800 participants were enrolled between December 2012 and
January 2013, 2 years after the PsA-TT mass vaccination cam-
paign, and sera from all participants were available for analysis.
The proportion of females in the pre- and postvaccination sur-
veys was similar (54% vs 57%), as was the mean household size
(15 [range, 1–47] vs 16 [range, 2–50]), the distribution of the
number of rooms per household (mean, 7.2 [range, 1–30] pre-
vaccination vs mean, 6.8 [range, 1–30] postvaccination), and the
average number of residents per room (2.5 vs 2.7) (Table 1). By
design, half of the participants in the prevaccination survey
lived in an urban area compared with all of the participants
in the postvaccination survey (Table 1). There was no statisti-
cally signiﬁcant difference between TT IgG GMCs (IU/mL)
from urban and rural areas prevaccination (P = .30, 2 sample
t test); these data are combined in the following analyses. All
but 4 (0.5%) of the postvaccinated survey participants self-re-
ported having received PsA-TT. Because we were interested in
population-level changes among targeted age groups following
the mass vaccination campaign, data from all participants, re-
gardless of self-reported vaccination status, are included in
the analyses.
Changes in TT IgG Pre- and Postvaccination
The distribution of pre- and postvaccination GMCs by age and
sex indicated that the minimum and maximum TT IgG concen-
trations observed were similar regardless of age, sex, or time of
survey (Figure 1). Prevaccination, the GMC was signiﬁcantly
higher among females aged 1–29 years (0.26 [95% CI,
.20–.33]) than males (0.13 [95% CI, .11–.16]) (P < .0001),
with the highest prevaccination GMCs observed among 18- to
29-year-old women (Table 2). There were statistically signiﬁ-
cantly higher IgG GMCs in all age–sex strata 2 years postvacci-
nation (Table 2). Postvaccination, the GMC point estimates
among all females aged 1–29 years (1.13 [95% CI, .97–.1.31])
were higher than among males (0.82 ([95% CI, .68–1.00]), al-
though the difference was not statistically signiﬁcant (P = .1).
Percentage Putatively Protected Pre- and Postvaccination
The percentage of participants with TT IgG levels indicative of
short-term protection (≥0.1 IU/mL) increased from 57.1%
prior to the vaccination campaign to 88.4% postvaccination, a
Table 1. Characteristics of Participants in Each Survey
Characteristic
Prevaccination
2010
Postvaccination
2012
No. % No. %
Age groupa,b
>1 y 31 4.0 . . . . . .
1–2 y 59 7.6 50 6.3
3–5 y 115 14.8 151 18.9
6–10 y 107 13.8 200 25.0
11–17 y 123 15.9 200 25.0
18–29 y 141 18.2 199 24.9
>29 y 199 25.7 . . . . . .
Sexb
Females 416 54.1 457 57.1
Residencec
Urban 394 49.7 800 100.0
Residents per household
>15 people 311 40.6 335 41.9
Rooms per household
>7 329 42.7 308 38.5
a The age given is age at enrollment for 2010 survey and age as of 1 December
2010 for postvaccination survey.
b Missing age and sex for 18 participants prevaccination.
c Compared to living in a rural area.
Figure 1. Box plot of tetanus toxoid immunoglobulin G (IU/mL) distribu-
tion before and after a meningococcal A polysaccharide–tetanus toxoid
protein conjugate vaccine mass vaccination campaign. The age given is
age at enrollment for 2010 survey and age as of 1 December 2010 for post-
vaccination survey.
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31.3-point increase (95% CI, 26.6–36.0; P < .0001; Table 3). The
age- and sex-speciﬁc proportions of participants pre- and post-
vaccination with evidence of short-term and long-term TT
immunity are shown in Figure 2. All age groups evidenced sta-
tistically signiﬁcant changes in the percentage with TT IgG lev-
els ≥0.1 IU/mL 2 years after PsA-TT introduction (Table 3).
Adolescents aged 11–17 years had the lowest proportion
(27.6% [95% CI, 19.7%–35.5%]), with evidence of short-term
protective levels of TT IgG pre–PsA-TT introduction and also
the greatest percentage difference 2 years later (56.9-point in-
crease [95% CI, 47.5–66.2]).
The proportion of participants with TT IgG levels indicative
of long-term protection increased from 20.0% prior to the
vaccination campaign to 58.5% postvaccination, a 38.5-point
increase (95% CI, 33.7–43.3; P < .0001). All age groups experi-
enced highly statistically signiﬁcant changes in the percentage of
participants who were putatively protected long-term 2 years
after PsA-TT introduction (Table 3).
However, despite these increases, 2 years after PsA-TT intro-
duction, 11.6% of participants still had TT IgG <0.1 IU/mL,
indicating no evidence of tetanus protection, and 41.5% had
TT IgG <1.0 IU/mL, indicating a lack of long-term protection.
Multivariate Logistic Regression Analysis
The 1345 participants aged 1–29 years at the time of PsA-TT
introduction were included in a multivariate logistic regression
model. These participants were drawn from 625 households.
The unadjusted odds of having a TT IgG level ≥0.1 IU/mL 2
years post–PsA-TT introduction vs prior was 5.7 (95% CI,
4.2–7.7; P < .0001), accounting for household clustering. After
accounting for age group, sex, and their interaction (which
was signiﬁcant and thus retained in the model [Wald test
P < .0001]), the adjusted odds of demonstrating short-term pro-
tection against TT 2 years after PsA-TT introduction vs prior
was 7.3 (95% CI, 5.2–10.2; P < 0.001). The results for long-
term protective concentrations ≥1.0 IU/mL were similar. The
unadjusted odds of having a TT IgG level ≥1.0 IU/mL 2 years
post–PsA-TT introduction vs prior was 5.6 (95% CI, 4.4–7.2,
P < .0001), accounting for household clustering. After also ac-
counting for age group, sex, and their interaction (which was
again signiﬁcant and retained in the model [Wald test
P < .0001]), the odds of demonstrating long-term protection
against tetanus 2 years after PsA-TT introduction vs prior
was 9.0 (95% CI, 6.6–12.2; P < .0001).
We also estimated the probability that an individual from
each age–sex strata would have evidence of short-term and
Table 2. Geometric Mean Concentrations of Tetanus Toxoid Immunoglobulin G (IU/mL) Before and After a Meningococcal A
Polysaccharide–Tetanus Toxoid Protein Conjugate Vaccine Mass Vaccination Campaign by Sex and Age Group
Age Group
Males Females
Prevaccination Postvaccination Prevaccination Postvaccination
No. GMC (95% CI) No. GMC (95% CI) P Valuea No. GMC (95% CI) No. GMC (95% CI) P Valuea
<1 y 16 .82 (.39–1.73) . . . . . . . . . 15 .55 (.17–1.82) . . . . . . . . .
1–2 y 35 .28 (.16–.47) 28 1.15 (.66–2.01) .0004 24 .26 (.16–.41) 22 1.64 (.74–3.61) .0001
3–5 y 63 .17 (.12–.23) 70 .68 (.46–.99) <.0001 52 .17 (.12–.24) 81 .89 (.64–1.24) <.0001
6–10 y 54 .12 (.08–.17) 106 .80 (.58–1.08) <.0001 53 .09 (.06–.14) 94 .81 (.61–1.08) <.0001
11–17 y 55 .07 (.05–.09) 84 .76 (.52–1.12) <.0001 68 .06 (.04–.10) 116 .64 (.47–.86) <.0001
18–29 y 42 .13 (.06–.26) 55 1.05 (.53–2.09) .0001 99 1.46 (.97–2.22) 144 2.38 (1.83–3.11) .04
>29 y 91 .06 (.04–.08) . . . . . . . . . 108 .40 (.27–.61) . . . . . . . . .
Data are shown as IU/mL.
Abbreviations: CI, confidence interval; GMC, geometric mean concentration.
a t test.
Table 3. Percentage Point Change in the Proportion of
Individuals With Evidence of Short- and Long-term Anti-Tetanus
Toxoid Immunity Before and After a Meningococcal A
Polysaccharide–Tetanus Toxoid Protein Conjugate Vaccine Mass
Vaccination Campaign
Age Groups
Percentage Point Change
in Short-term (≥0.1 IU/mL)
TT Immunity
Percentage Point Change
in Long-term (≥1.0 IU/mL)
TT Immunity
% (95% CI) P Value % (95% CI) P Value
1–2 y 14.0 (1.1–27.0) .0442 58.4 (43.2–73.6) <.0001
3–5 y 22.0 (12.4–31.7) <.0001 44.7 (35.5–53.9) <.0001
6–10 y 41.8 (31.3–52.2) <.0001 46.4 (38.2–54.8) <.0001
11–17 y 56.9 (47.5–66.2) <.0001 38.9 (30.4–47.3) <.0001
18–29 y 17.1 (8.6–25.6) <.0001 23.8 (13.8–33.8) <.0001
Overall 31.3 (26.6–36.0) <.0001 38.5 (33.7–43.3) <.0001
Abbreviations: CI, confidence interval; TT, tetanus toxoid.
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long-term immunity before and after PsA-TT introduction
from the ﬁnal models. In 2010, prior to PsA-TT introduction,
both males and females <18 years of age had very similar
age-speciﬁc probabilities of achieving short-term protection
(Figure 3A) and long-term protection (Figure 3B). The proba-
bility of short-term protection decreased with increasing age
across these groups prevaccination. The probability of both
short-term and long-term protection was signiﬁcantly higher
among women compared with men aged 18–29 years. The
probability of reaching both short-term and long-term protec-
tion was statistically signiﬁcantly greater in all age–sex strata
after the PsA-TT mass vaccination campaign (Figure 3).
DISCUSSION
We found signiﬁcantly higher TT immunity 2 years following
the PsA-TT mass vaccination campaign in Mali across all age
groups targeted for vaccination. Before PsA-TT introduction,
TT immunity was low across all age groups, although higher
in females than males and highest in women aged 18–29
years, who are likely to have received TT vaccination during
pregnancy. Two years after PsA-TT introduction, TT GMCs
and the proportion with both short-term and long-term protec-
tion against tetanus increased signiﬁcantly across all groups tar-
geted for PsA-TT vaccination. After accounting for age and sex,
the odds of having at least short-term protection were 7.3 times
higher and the odds of long-term protection were 9 times high-
er after PsA-TT introduction, indicating signiﬁcant boosting of
tetanus immunity in the population, which persisted 2 years
after the campaign ended.
Our results are consistent with evidence from PsA-TT clini-
cal trials that have demonstrated signiﬁcant boosting of TT
immunity among vaccine recipients 4 weeks after vaccination
[22]. Criteria for inclusion in these clinical trials required par-
ticipants to have completed all EPI vaccines; in contrast, in our
study 42.8% (95% CI, 39.3%–46.3%) of participants demon-
strated no evidence of tetanus immunity prior to PsA-TT intro-
duction. Nevertheless, we found signiﬁcant evidence of
boosting of tetanus immunity over the 2-year study period.
A limitation of our study is that we were unable to obtain in-
formation about individual-level history of vaccination with
TT-containing vaccines. Thus, we cannot be certain that the
higher immunity observed after the vaccination campaign indi-
cates an anamnestic response or whether it is indicative of a
combination of anamnestic responses and prolonged response
to primary immunization in some ages. A key question is
whether the boosting of tetanus immunity observed is causally
related to the introduction of PsA-TT or whether vaccination
with other TT-containing vaccines could account for the in-
crease in immunity observed. Examining our ﬁndings in light
of routine immunization coverage data suggests that coverage
with TT-containing vaccines remained relatively constant dur-
ing this 2-year period and supports our claim that PsA-TT
boosted tetanus immunity. WHO-UNICEF estimates that in
2010, 18% of children aged 12–23 months in Mali had received
any doses of tetanus-containing vaccine and 24% had not
Figure 2. Tetanus toxoid immunoglobulin G (IgG) levels (IU/mL) by sex and age group before and after a Meningococcal A Polysaccharide–Tetanus Toxoid
Protein Conjugate Vaccine mass vaccination campaign.
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received all 3 recommended EPI doses [11], which is consistent
with our ﬁndings that 22% (95% CI, 12.3%–34.7%) of 1- to 2-
year-olds sampled in the 2010 survey had TT IgG concentra-
tions <0.1 IU/mL. In addition, estimated coverage in the ﬁrst
2 years of life with 1 dose of TT-containing vaccine remained
relatively constant, between 82% and 87% over the period
2002–2012 [11]. Some of the women in the reproductive age
group who participated in this study would have received TT
during pregnancy, so the increase in antibody concentrations
seen in women of reproductive age at the population level fol-
lowing the vaccination campaign could be due primarily to an
anamnestic response in subjects who had previously received at
least 1 dose of TT. Therefore, it is possible that the signiﬁcant
increase in tetanus immunity among adult females is due to a
combination of TT vaccination in pregnancy and PsA-TT. In-
dividuals >1 year of age would not be eligible for TT-containing
vaccines (unless targeted for vaccination during pregnancy)
and, as there is no naturally acquired tetanus immunity, we
can attribute the signiﬁcant increases in tetanus immunity ob-
served in young children and adolescents of both sexes and in
adult males to the impact of PsA-TT. Overall, the proportion of
the population with long-term immunity against tetanus re-
mains low, which may be explained by limited exposure to
the primary tetanus vaccination series historically in this
population.
Our evidence suggests that polysaccharide-protein conjugate
vaccines containing TT such as PsA-TT boost tetanus immunity
and should be considered bivalent vaccines. Introduction of these
vaccines in widespread population campaigns can help increase
tetanus immunity across age groups not typically targeted for
TT-containing vaccines or when coverage with TT vaccines is
suboptimal. Recognition of this added beneﬁt of PsA-TT could
inform future vaccination strategies in resource-limited settings
where maintaining high tetanus immunity, in addition to pre-
venting meningococcal disease, is a priority.
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